Published: 4 April 2019

Committees

Comments on agenda items for the 62nd meeting of the Medicines Classification Committee to be held on 11 April 2019

The Medicines Classification Committee and the Secretary wish to thank everyone for their valuable input and feedback on all agenda items.

A total of two submissions commenting on agenda items for the 62nd meeting were received (PDF, 3.90 MB, 4 pages).

Agenda item 6.1 Ropivacaine up to 7.5 mg/mL, solution for injection – proposed reclassification from prescription medicine to prescription except classification

Two comments were received about this agenda item.

It was also brought to Medsafe’s attention that the description for the agenda item had incorrectly described ropivacaine up to 10mg/mL and this has since been corrected.

Agenda item 6.2 Bupivacaine up to 0.5% w/v in combination with adrenaline – proposed reclassification from prescription medicine to prescription except classification

One comment was received about this agenda item in support of this proposal.